This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MAX R. GREENLEE, M.D.; WILLIAM L. EPSTEIN, M.D.

AMA Arch Derm. 1959;79(3):350-351.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Treatment of uncomplicated psoriasis with steroids in general is unsatisfactory.^1,2 Recently, however, a new corticosteroid, triamcinolone,^* has been marketed and from clinical trials appears to have a dramatic effect in relatively low doses.^3-5 This remarkable observation prompted us to investigate the drug in a group of psoriatics under rigid experimental conditions.

Methods

Thirty-four patients with uncomplicated but recalcitrant psoriasis of 10 or more years' duration volunteered to be subjects. The experimental plan called for one group to receive 4 mg. four times a day for a month; a second group, 4 mg. daily, and a third group, a placebo. All other therapy was discontinued. At the end of one month, the treatment schedule was arbitrarily changed. At random, some patients received 8 mg. daily, some a placebo, and some nothing. In the third month, all treatment was stopped and follow-up observations were made. The subjects . . . [Full Text PDF of this Article]

Author Affiliations
San Francisco

From the Subdepartment of Dermatology, Department of Medicine, University of California School of Medicine.

Footnotes
Submitted for publication July 30, 1958.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?